TruScreen to Present at Singapore Healthcare Day Forum

NZX/ASX Announcement
24/03/2025
TruScreen to Present at Singapore Healthcare Day Forum
• Marty Dillon, CEO of TruScreen is presenting the company’s innovative AI enabled cervical
cancer screening technology at the Singapore Healthcare Day Forum
• The Presentation focuses on the global recognition of the TruScreen tonology and of its
successes to date for Low- and Middle-Income Countries

TruScreen Group Limited (“TruScreen” or “the Company”) advises that its CEO, Marty Dillon is an invited
presenter at the Healthcare Day Forum held in Singapore on Monday March 24, 2025.
Mr Dillon’s presentation is attached for the information of stakeholders.


TruScreen CEO, Marty Dillon commented:
This invitation follows on from a watershed 2024 year where TruScreen received recognition for our
cervical cancer screening technology from leading global organisations such as the World Health
Organization, UNITAID, Chinese Obstetricians and Gynaecologists Association (COGA) and the Chinese
Society of Colposcopy and Clinical Pathology (CSCCP). TruScreen is proud to be one of only six
Australian medtech companies invited to showcase our innovative technology at this forum. TruScreen
will continue to work with its global distributors to assist with achieving the WHO strategic objective of
eliminating cervical cancer by the end of the century.
Cervical cancer is the 4
th
highest cancer causing deaths amongst women and accounts for in excess of
350,000 global deaths per annum in the past years.

This announcement has been approved by the Board.

Ends
For more information, visit www.truscreen.com or contact:
Martin Dillon
Chief Executive Officer
martindillon@truscreen.com
Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical cancer
screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA
(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS
(Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines,
among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing
facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical
Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National
Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the
Russian guidelines for the screening of cervical cancer.
In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To
date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and
Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the
cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to
preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a
microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-
procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix,
onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can
be done at the same time, such as the human papillomavirus (HPV)
test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same
sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked
to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test
may also be done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence
or absence of a condition. If individuals who have the condition are considered "positive" and those who
don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives
and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on the
individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and
Australia, please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)
Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council

---

SINGAPORE2025
24 March 2025

Who is TruScreen
The TruScreenTechnology
Why TruScreen
TruScreen Sales and Growth Strategy

Who is TruScreen
Enabled by AI, TruScreenprovides an
accurate, real time cervical cancer
screening solution

4
4
Who is TruScreen
TruScreen Group Ltd is listed
on both the Australian (ASX)
and New Zealand (NZX) stock
exchanges, with a common
ticker code of TRU.
Shares on Issue:
552,591,116
Market Capitalisation at
27 February 2025:
NZD $19.34m
TruScreen Group Ltd is a
revenue generating Life
Science company with FY24
annual sales exceeding
NZD $2m.
TruScreen Group Ltd owns
TruScreen Pty Ltd, the
Australian operating company
that manufactures and
markets the TruScreen cervical
cancer screening system

5
5
Corporate Snapshot
Shares on issue552 million
Options13 million
Share priceNZ$0.035
Market capitalisationNZ$19.34 million
52 week high3.7 cents
52 week low1.5 cents
Major ShareholdersShares%
New Zealand Depository Nominee64,098,83311.6
Consolidated Nominees39,602,4007.17
Masfen Securities Limited29,050,3695.26
Bhagwanji Bhula Rama27,791,6665,03
New Zealand Central Securities27,539,5664.98
Ryan Peter Parkin20,020,0003.62
David and Adrienne Stewart12,630,0002.29
TruScreen Price History (NZX)

6
2025 & BeyondBuilding for the Future 2020-2024
Building the Fundamentals 2014 - 2020
The TruScreen Journey
China Growth continues
Distribution of Dalton Bio IVD HPV DNA products
Vietnam HPHA program targets 260,000 women,
Uzbekistan and Zimbabwe screening programs to
commence.
Indonesia and ASEAN commence commercial use
Global focus on AI boosts recognition of TruScreen
523% sales
growth in H1
2018 Oct
Recognition by
World Health
Organization
2019 May
2020 Jan
ASX Listing
2014 Nov
Listing on NZAX
2023-24
COGA Blue Book and CSCCP Guidelines include TruScreen
UNITAID recognises TruScreen’s value for Cervical Cancer screening
WHO invited TruScreen to participate in Key AI meeting for cervical cancer
screening
Vietnam – HPHA large scale screening MOU signed
2018 Jul
Comence large
scale pilot
programs in China
with CDC and COG
2018 Dec
Migration to NZX
2022
Managing COVID-19 challenges
Cost reduction
Manufacturing and business
development in China
Completion of major COGA study
Strengthen distributor
arrangement in Vietnam
CFDA (NMPA)
approval for second
generation device
2017 Dec

The TruScreen Technology

8
Handheld device (HHD)
Intelligent Cradle
Single Use Sensor (SUS)
•Each TruScreen examination takes one to two minutes to produce results, compared to
conventional Pap tests which can take days, weeks, or even months in some countries, for a
result to be returned.
•Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution

9
a pen-like wand covered by a
Single Use Sensor (SUS) is used
to gently touch multiple spots on
the cervix. The SUS contains a
precision lens and electrodes
which interfaces with the cervix.
It sends and picks up low level
electrical and optical signals (14
readings per second) from the
cervical tissue.
1
How it works

10
The TruScreen Handheld Device (HHD) then applies
an integrated AI-enabled algorithm to analyse
these signals and compares them to an integrated
database of patients drawn from a wide range of
geographic and ethnic backgrounds with differing
histological diagnoses.
This identifies the presence of abnormal (cancerous
and pre-cancerous) cells in the cervix and provides
physicians with real-time results.
2
How it works

11
✓Clinicians/physicians are able to immediately plan
appropriate patient care
✓Device has an expected life span of 5–7 years
✓Disposable SUS is used once per test per patient - ensures
there is no chance of cross-infection between patients
✓The entire patient data collection and analysis is self-
checked and controlled. No tissue sample needs to be
taken. These measures ensure that the results are reliable
and consistent, and that the examination is painless and
safe
✓TruScreen has been used on over 1 million women and there
has never been a single adverse event reported

Why Truscreen

13
Extensive body of clinical evidence
Over 40,000 women in clinical trials to date***
***Total number of subjects across published and unpublished clinical studies in English, data from TruScreen device generation I and II
YearCountryInvestigatorN
2002ChinaDr Huang Yi683
2002ChinaDr Wang Ziyao301
2003UK/Aus Prof A. Singer651
2008Poland Dr. Pruski234
2009ChinaProf Ding Ma302
2010ChinaDr. He Xiu-Kui392
2010ChinaProf Fengnian Rong532
2010Korea Dr. Hyeong Soo Lim292
2011Poland Dr. Pruski293
2011ChinaDr. Li Xia500
2015Turkey Dr. Özgü E285
2016ChinaDr. LI Pei,368
2017Mexico Dr. Ricardo Lua521
2018ChinaDr. Huixia Yang2730
2018-2021China54 Hospitals14,982
YearCountryInvestigatorN
2019ChinaDr. Baojin Wang315
2019ChinaDr. Wei Zhang1030
2019ChinaDr. Yanhong Jia320
2020ChinaDr Kang Yanan192
2021ChinaProf Chen Fei974
2021ChinaDr Wei Yingting458
2022ChinaDr Chen Zhenbo476
2022ChinaDr Zhu Bo283
2022ChinaDr Zhao Yuqian1319
2022AustraliaDr Jessica Vet506
2023ChinaDr Luo Lianmei318
2023ChinaDr Liu Hang997
2024ChinaDr Yang Yueming489
2024ChinaDr Fengyi Xiao & Long Sui1908
2024Saudi ArabiaDr S Maqsood and DrM Alhudhud507

14
•TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV
•TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method
•TruScreen was determined to be an appropriate primary cervical cancer screening tool in regions with high morbidity and
mortality to cervical cancer
•Also highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a
TruScreen-HPV co-testing. The size of the COGA study, which was TruScreen’s largest clinical evaluation to date, lends extra significance to its
results and broad conclusions.
TruScreen’s
sensitivity
was well above that for LBC
(87.5% v’s 66.5%), with a high
degree of statistical
significance (p<0.001).
TruScreen’s
specificity
(88.4%) was higher than
both LBC (86.3%) and hrHPV
testing (78.3%) (also at
p<0.001).
The sensitivity of TruScreen-hrHPV co-
testing (carrying out with multiple types
of screening tests at the same time, as
opposed to a single type) was higher
than that of LBC-hrHPV co-testing,
98.4% vs 95.9%
(statistically significant at p=0.006).
COGA Trial (n= 15,661, 2018-2021)

4

15
Why TruScreen?
TruscreenLiquid Based Cytology (LBC)HPV DNA
Real time results
Low infrastructure costs
Strong clinical results
Objective results
Low training threshold
Portable
No cell or tissue
samples taken

TruScreen Sales & Growth
Strategy

17
17
TruScreen Financials
KEY FINANCIALS
NZD (m)
FY 22
Actual
FY 23
Actual
FY 24
Actual
Sales1.71.662.1
Total Revenue2.72.22.6
COGS1.31.31.4
R&D1.50.90.9
EBITDA-2.7-2.4-2.0
Write off of Non-Current
Assets
-4.6-0.05-
Amortisation &
Depreciation
-0.6--
LOSS FOR YEAR-7.9-2.4-2.0
Net Assets3.42.53.2
Cash2.82.22.7
⚫Sales increased 27% YOY
⚫SUS Sales increased 25% YOY
⚫Revenue increased 18% YOY
⚫EBITDA improved 15% YOY
⚫Net Assets increased 28% YOY
⚫Cash increased 23% YOY
⚫China SUS/Device Pull Through increased 40% YOY
FY 24 v FY 23

18
18
TruScreen Financials
1
st
Half FY241
st
Half FY25% Change
Sales$0.98$1.035%
EBITDA-$1.35-$1.1316%
Operating Cash Outflow-$1.4- $0.936%
SUS Units91,620 96,480 5%
Devices429-79%
China SUS pull though
per month per device9713741%

19
Recurring Revenue Model
•TruScreen manufactures two devices –
oone made in China for use in China, where locally manufactured products
have preferential market access
oone made in Australia for other markets
•For each patient screened with the TruScreen device a new disposable Single
Use Sensor (SUS) must be used. This creates a recurring revenue model with a
consumable sale for each patient screened with TruScreen.

20
TruScreen Sales Strategy
•Whilst many other medical technology companies seek to commercialize their devices
in developed countries, TruScreen focuses on Low and Middle Income Countries (LMICs)
such as China, Mexico, Vietnam and Zimbabwe.
•Unlike the developed western markets, these countries and other LMICs have no or
minimal large-scale cervical cancer screening programs and infrastructure. This
creates a gap in the market for TruScreen that is not available in the developed
markets and allows quicker market access from a relative lack of existing
competition.
•Unlike competing products such as cytology and HPV DNA screening TruScreen is
‘capital light’, not requiring lab infrastructure to be established prior to commencing
screening.

21
World Health Organisation (WHO)
Unitaid
Clinton Health Access Initiative
Daffodil Foundation - Australia
China Obstetrics and Gynaecology
Association
China Society for Colposcopy and
Cervical Pathology
Russia Cervical Cancer Screening
Guideline
Vietnam Hospital Technical List
•CE Mark, European Union
•NMPA, China
•TGA, Australia
•MHRA, UK
•SFDA, Saudi Arabia
•Roszdravnadzor, Russia
•COFEPRIS, Mexico
•WAND New Zealand
•Zimbabwe Ministry of Health
•IEAKI Indonesia
•Vietnam Ministry of Health
TruScreen Regulatory Approvals
ISO 13485
ISO 60601-1-2
CE Mark
International Approvals:Recogized by
International Quality
Accreditation:

22
Market Expansion
FY 24 TruScreen sales grow 27% YOY, exceeding China and APAC CAGR forecasts for HPV screening (10%).
Business Market Insights
June 2023:
The Asia Pacific CIN & HR-HPV
treatment market is expected to grow
from US$ 2,738.94 million in 2023 to US$
3,949.99 million by 2028.
It is estimated to grow at a CAGR of
7.6% from 2023 to 2028.
1
2
HPV Test Market Revenue (Million USD) and Growth Rate (2018-2028)

23
0
50
100
150
200
250
300
350
0
50
100
150
200
250
300
FY19FY20FY21FY22FY23FY24FY25FY26
Installed Devices
SUS Usage
Thousands
Field1
'SUS Usage', 'Installed Devices' by 'Field1'
Installed DevicesSUS Sales
Device installations and SUS Sales
Where we are

24
TruScreen’s presence and global markets
China
477M
RUSSIA
48M
&
CENTRAL ASIA
13M
ASEAN &
INDONESIA
142M
MEXICO
46M
VIETNAM
36M
SAUDI
11M
SOUTHERN
& CENTRAL
AFRICA
134M
INDIA
468M
UZBEKISTAN
12M

25
Growth Strategies
Market expansion to continue with China the key focus
Focus on key growth provinces (Shandong, Jiangsu,, Hunan, Zhejiang, Guangdong,
Guangxi) - Total population 496m
Strengthen China Distribution Capability via Strategic Partnership with DaltonBio
Strengthen vertical Asian market from Indonesia through China
Target Govt and NGO funded programs in Zimbabwe, Vietnam, Mexico and Uzbekistan

26
Reduce SUS and Device COGS and increase margins
Focus on countries with limited or nil cervical screening capability
Developing strategic partnerships for complementary woman’s health services
Capitalise on global focus on AI enabled cervical cancer technologies – e.g. WHO
Expand product portfolio to include Dalton Bio HPV related IVD products DNA tests,
including HPV DNA tests and self sampling
Build on International NGO Recognition (WHO, UNITAID, CHAI, COGA , CSCCP) to build
acceptance and remove barriers to sale

27
TruScreen & Dalton Bioscience
MOU signed February 2025 between TruScreen Group Ltd and Hangzhou Dalton
Bioscience
1.TruScreen to distribute globally (excluding USA and Canada) via selected distributors
DaltonBio HPV related IVD products including DNA tests and Self Sampling.
2.DaltonBio to explore opportunities to assist TruScreen’s AI enabled real time cervical
screening device within its distribution network, notably its 200 SUB distributors in China
and regulatory and distribution partners in South America

28
Contact us for more Information
Guy Robertson
Chief Financial Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com
Martin Dillon
CEO
M - +61 449 115 065
E – martindillon@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com

29
Disclaimers
This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about
the Company and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be
complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company. This presentation should
be read in conjunction with the Company’s annual report, market releases and other periodic and continuous disclosure announcements, which are available at
www.nzx.com. This presentation does not constitute an offer, advertisement or invitation in any place in which, or to any person to whom, it would not be lawful to make
such an offer, advertisement or invitation.
Not financial product advice
This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire the Company’s securities, and has been
prepared without taking into account the objectives, financial situation or needs of prospective investors. Before making an investment decision, prospective investors
should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and consult a financial adviser, solicitor,
accountant or other professional adviser if necessary.
Past performance
Any past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future
performance. No representations or warranties are made as to the accuracy or completeness of such information.
Future performance
This presentation includes certain “forward-looking statements” about the Company and the environment in which the Company operates. Forward-looking information
is inherently uncertain and subject to contingencies, known and unknown risks and uncertainties and other factors, many of which are outside of the Company’s control,
and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. A number of important factors
could cause actual results or performance to differ materially from any forward-looking statements. No assurance can be given that actual outcomes or performance
will not materially differ from the forward-looking statements. The forward-looking statements are based on information available to the Company as at the date of this
presentation. Except as required by law or regulation (including the Listing Rules), the Company undertakes no obligation to provide any additional or updated
information whether as a result of new information, future events or results or otherwise.

30
References
1.WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news-room/fact-
sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
2.WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020
3.Human papillomavirus and cancer (who.int)
4.Wei, Y., Wang, W., Cheng, M., Hong, Z., Gu, L., Niu, J., Di, W., & Qiu, L. (2021). Clinical evaluation of a real-time optoelectronic
device in cervical cancer screening.European journal of obstetrics, gynecology, and reproductive biology,266, 182–186.
https://doi.org/10.1016/j.ejogrb.2021.09.027.
5.Vet, J. N., Haindl, J. P., Velasquez, C., Parker, L. J., Burns, M. I., Morrell, S., & Campion, M. J.. (2022). A Performance Evaluation
of an Optoelectronic Cervical Screening Device in Comparison to Cytology and HPV DNA Testing.European Journal of
Gynaecological Oncology,43(2), 213. https://doi.org/10.31083/j.ejgo4302027
6.Central Intelligence Agency, The World Fact Book, CHINA, People and Society, Female ages 25-64 Years, visited 28 August
2020, https://www.cia.gov/library/publications/the-world-factbook/geos/ch.html
7.Central Intelligence Agency, The World Fact Book, VIETNAM, People and Society, Female ages 25-64 Years, visited 28 August
2020, https://www.cia.gov/library/publications/the-world-factbook/geos/vm.html